Tae‐You Kim

机构：Seoul National University of Science and Technology, Cancer Research Institute, Seoul National University Hospital, National University College · ORCID：0000-0002-9986-2684

发表论文 190 篇 · 总被引 20697 次 · h-index 48

代表论文

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 346)
• Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer (2023 · British Journal of Cancer · 被引 34)
• International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). (2024 · Journal of Clinical Oncology · 被引 25)
• Practical Utility of Liquid Biopsies for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer (2023 · Cancers · 被引 18)
• Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis (2024 · Journal of Liver Cancer · 被引 11)
• Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non–Small Cell Lung Cancer (2024 · Cancer Research and Treatment · 被引 10)